Anticoagulation Therapy (Record no. 9718)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03155nam a22002777a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240305192633.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 230113b |||||||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9789535126669 |
| International Standard Book Number | 9535126660 |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | DLC |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | English |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615 |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Ozcan Basaran |
| 9 (RLIN) | 48026 |
| 222 ## - KEY TITLE | |
| Key title | Common terms and phrases |
| Qualifying information | acenocoumarol acid anticoagulant effect anticoagulant reversal antithrombin apixaban assays assessment associated atrial fibrillation Beriplex Biochem bleeding models blood coagulation cell chiral Clin clinical clotting factors compared coumarinic cytochrome D-dimer dabigatran disease drug edoxaban efficacy embolism enantiomers enzymatic epoxide reductase factor IX factor VIIa factor Xa factor Xa inhibitors gene genetic hemorrhage hemostasis heparin heparin bridging human implantation increased infusion inhibition interaction intracranial IU/kg K-dependent coagulation factors major bleeding mechanism metabolism microsomal ml/min molecule NOACs NVAF oral anticoagulants p-GP patients pharmacokinetics phenprocoumon plasma polymorphism pregnancy procoagulant prophylaxis protein prothrombin complex concentrate recombinant factor VIIa renal reversal agent reversal of anticoagulation rivaroxaban rodenticides rodents surgery target Thromb Haemost Thromb Res thrombogenic thrombogenic risk factors thrombophilia thrombotic treatment trial venous thromboembolism venous thrombosis vitamin K vitamin K epoxide vitamin K-dependent coagulation vitamin Kantagonists vitro vivo VKOR activity VKORC1 mutations warfarin warfarin resistance |
| 245 ## - TITLE STATEMENT | |
| Title | Anticoagulation Therapy |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | New York: |
| Name of publisher, distributor, etc. | BoD – Books on Demand, |
| Date of publication, distribution, etc. | c2016 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 150 pages |
| 505 ## - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Contents:<br/><br/>Comparative Biology of the Resistance to Vitamin<br/> <br/> <br/>The Risk Factors of Thrombogenic Thrombophilia and<br/> <br/> <br/>Management of Anticoagulation Around Cardiac Implantable<br/> <br/> <br/>Prothrombin Complex Concentrate a General Antidote for Oral<br/> <br/> <br/>NonVitamin K Antagonist Oral Anticoagulants in Atrial<br/> <br/> <br/>NonVitamin K Antagonist Oral Anticoagulants Clinical Use<br/> <br/> <br/> |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists. |
| 600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME | |
| General subdivision | Medical / Nursing / Pharmacology |
| 9 (RLIN) | 28586 |
| General subdivision | Medical / Critical Care |
| 9 (RLIN) | 27035 |
| General subdivision | Medical › Nursing › Pharmacology |
| 9 (RLIN) | 47517 |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 48027 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | ddc |
| Koha item type | E-BOOKS |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Collection | Home library | Current library | Shelving location | Date acquired | Total checkouts | Full call number | Barcode | Date last seen | Copy number | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | 01/13/2023 | 615 | EBS13766 | 01/13/2023 | EBS13766 | 01/13/2023 | E-BOOKS |